What is Replimune Group's market cap?

Replimune Group (REPL) has a market capitalization of $932.6M and trades on NASDAQ.

Who are Replimune Group's competitors?

Replimune Group's key competitors include Amgen, Regeneron Pharmaceuticals, Oncolytics Biotech, Inc. Common Shares, and others. These companies compete in similar markets and product categories.

Who does Replimune Group partner with?

Replimune Group's notable partners include Bristol Myers Squibb Company, Roche, Merck & Co..

Where is Replimune Group headquartered?

Replimune Group is headquartered in United States of America and employs approximately 331 people. It has been publicly traded since 2018.

Replimune Group

REPL

Replimune Group is a clinical-stage biotechnology company focused on developing a novel class of cancer treatments known as oncolytic immunotherapies.

Market cap

$932.63M+12.3%

Net income-$314.9M-38.0%

Free cash flow-$283.3M-47.6%

EPS (diluted)-$3.44-12.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q4 2026 report

June 29, 2026

EPS-$0.76Miss by $0.10

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$13.6M

EPS estimate-$0.64

Financials

Q3 2026

Income statement

See full

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Balance sheet

See full

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Cash flow

See full

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Valuation & ratios

Valuation

See full

Market cap$932.63M+12.3%

Enterprise value$887.18M+22.5%

Returns & leverage

See full

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Competitors

By market cap

Amgen$196.25B+24.6%

Regeneron Pharmaceuticals$70.0B+20.5%

CG Oncology$6.5B+223%

Replimune Group$932.6M+25.4%

Prelude Therapeutics$391.1M+759%

Genelux Corporation$133.6M+22.1%

Oncolytics Biotech, Inc.$109.8M+22.4%

Theriva Biologics$10.8M+176%

By revenue growth

CG Oncology+666%

Amgen+9.1%

Regeneron Pharmaceuticals+5.9%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Amgen20.96%+3.6pp

CG Oncology-3,682.61%+12,263pp

Profile

Replimune Group is a clinical-stage biotechnology company focused on developing a novel class of cancer treatments known as oncolytic immunotherapies. Utilizing its proprietary RPx platform based on an engineered herpes simplex virus 1 (HSV-1) backbone, the company designs therapies that selectively replicate in and kill tumor cells while simultaneously activating a systemic, patient-specific immune response. Its primary value proposition lies in an "off-the-shelf" approach that bundles multiple immune-activating mechanisms into single therapies to improve outcomes in difficult-to-treat cancers.

Competitive position

A leading specialist in HSV-1 based oncolytic platforms with a lead candidate (RP1) under priority review by the FDA for advanced melanoma.

GeographiesGlobal, United States

Customer segmentsHealthcare providers, Cancer patients

Business modelR&D-stage biotechnology, Licensing and collaboration

SuppliersSpecialized viral manufacturing facilities, Raw material suppliers for genetic engineering, Clinical trial site operators

CustomersOncology clinics, Specialty pharmacies, Large pharmaceutical partners for commercialization

CountryUnited States of America

Listed2018

Employees331.0

CEOSushil Patel

SectorHealthcare

IndustryBiotechnology

Websitereplimune.com

FilingsSEC EDGAR

Questions, answered.

What is Replimune Group's market cap?: Replimune Group (REPL) has a market capitalization of $932.6M and trades on NASDAQ.
Who are Replimune Group's competitors?: Replimune Group's key competitors include Amgen, Regeneron Pharmaceuticals, Oncolytics Biotech, Inc. Common Shares, and others. These companies compete in similar markets and product categories.
Who does Replimune Group partner with?: Replimune Group's notable partners include Bristol Myers Squibb Company, Roche, Merck & Co..
Where is Replimune Group headquartered?: Replimune Group is headquartered in United States of America and employs approximately 331 people. It has been publicly traded since 2018.